Humacyte, Inc. (HUMA)
1.045
-0.30
(-22.01%)
USD |
NASDAQ |
Jun 11, 13:57
Humacyte SG&A Expense (Quarterly) : 7.93M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 7.93M |
| December 31, 2025 | 7.616M |
| September 30, 2025 | 7.61M |
| June 30, 2025 | 7.809M |
| March 31, 2025 | 8.136M |
| December 31, 2024 | 7.432M |
| September 30, 2024 | 7.307M |
| June 30, 2024 | 5.746M |
| March 31, 2024 | 5.314M |
| December 31, 2023 | 6.002M |
| September 30, 2023 | 6.07M |
| June 30, 2023 | 6.191M |
| Date | Value |
|---|---|
| March 31, 2023 | 5.234M |
| December 31, 2022 | 5.833M |
| September 30, 2022 | 6.188M |
| June 30, 2022 | 5.18M |
| March 31, 2022 | 5.682M |
| December 31, 2021 | 5.554M |
| September 30, 2021 | 5.398M |
| June 30, 2021 | 5.391M |
| March 31, 2021 | 4.787M |
| December 31, 2020 | 2.597M |
| September 30, 2020 | 3.435M |
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Altimmune, Inc. | 8.052M |
| Protalix Biotherapeutics, Inc. | 3.051M |
| Agenus, Inc. | 6.86M |
| Amgen, Inc. | 1.602B |
| BioCryst Pharmaceuticals, Inc. | 94.55M |